Ind-Swift Labs.
NSE: INDSWFTLAB · Pharmaceuticals
Snapshot
Unlock Ind-Swift Labs.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Ind-Swift Laboratories Limited is an Indian pharmaceutical company specialising in the development, manufacture, and sale of active pharmaceutical ingredients (APIs) across a diverse range of therapeutic areas. The company also provides comprehensive contract research and manufacturing services, including process development and analytical support.
Business Model
The company generates revenue through the large-scale production and sale of APIs and by offering contract manufacturing and custom synthesis services to global pharmaceutical partners. It leverages its research and development capabilities to provide reference standards and impurity profiling for complex chemical compounds.
Growth Outlook
Growth is driven by the expansion of its API portfolio and the strengthening of its contract manufacturing and custom synthesis service offerings. The company continues to focus on regulatory support and process research to cater to both domestic and international markets.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent international quality standards and potential inspections by global health authorities.
- Raw Material Price Volatility. Fluctuations in the cost of key starting materials and chemical intermediates can adversely impact profit margins.
- Competitive Pressure. The API manufacturing sector is highly competitive, with pricing pressures from global generic manufacturers affecting market share.
- Currency Risk. As an exporter, the company is exposed to foreign exchange rate volatility which may affect its financial performance.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Ind-Swift Labs. and 5,000+ companies — free.
Key Metrics
REVENUE
₹626 Cr
TTM · consolidated
NET PROFIT
₹41 Cr
TTM · consolidated
EPS
₹5.26
TTM · consolidated
RETURN ON EQUITY
3.4%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
4.0%
TTM · consolidated
P/E
44.5x
Q4 FY26 · consolidated
EV/EBITDA
17.6x
Q4 FY26 · consolidated
EBITDA MARGIN
14.7%
TTM · consolidated
NET PROFIT MARGIN
8.9%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Ind-Swift Labs.INDSWFTLAB | 1,168 | 44.47 | 17.62 | 226.0% | 14.7% | 3.4% | 4.0% | +121.7% |
Jagsonpal PharmaJAGSNPHARM | 1,216 | 35.45 | 21.17 | 6.9% | 24.4% | 17.3% | 22.4% | -7.9% |
Lincoln Pharma.LINCOLN | 1,173 | 13.71 | 9.06 | 7.7% | 19.5% | 12.7% | 16.4% | +7.8% |
Venus RemediesVENUSREM | 1,157 | 23.25 | 14.80 | 18.0% | 20.9% | 17.5% | 22.1% | +239.7% |
Hester BiosHESTERBIO | 1,150 | 36.08 | 23.45 | 6.9% | 29.0% | 17.6% | 15.2% | +31.0% |
Sakar HealthcareSAKAR | 1,148 | 65.52 | 28.44 | 41.8% | 28.3% | 10.3% | 13.3% | +148.6% |
As of Q4 FY26
Financials
Ind-Swift Labs.
NSE: INDSWFTLAB · Pharmaceuticals
Snapshot
Unlock Ind-Swift Labs.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Ind-Swift Laboratories Limited is an Indian pharmaceutical company specialising in the development, manufacture, and sale of active pharmaceutical ingredients (APIs) across a diverse range of therapeutic areas. The company also provides comprehensive contract research and manufacturing services, including process development and analytical support.
Business Model
The company generates revenue through the large-scale production and sale of APIs and by offering contract manufacturing and custom synthesis services to global pharmaceutical partners. It leverages its research and development capabilities to provide reference standards and impurity profiling for complex chemical compounds.
Growth Outlook
Growth is driven by the expansion of its API portfolio and the strengthening of its contract manufacturing and custom synthesis service offerings. The company continues to focus on regulatory support and process research to cater to both domestic and international markets.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent international quality standards and potential inspections by global health authorities.
- Raw Material Price Volatility. Fluctuations in the cost of key starting materials and chemical intermediates can adversely impact profit margins.
- Competitive Pressure. The API manufacturing sector is highly competitive, with pricing pressures from global generic manufacturers affecting market share.
- Currency Risk. As an exporter, the company is exposed to foreign exchange rate volatility which may affect its financial performance.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Ind-Swift Labs. and 5,000+ companies — free.
Key Metrics
REVENUE
₹626 Cr
TTM · consolidated
NET PROFIT
₹41 Cr
TTM · consolidated
EPS
₹5.26
TTM · consolidated
RETURN ON EQUITY
3.4%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
4.0%
TTM · consolidated
P/E
44.5x
Q4 FY26 · consolidated
EV/EBITDA
17.6x
Q4 FY26 · consolidated
EBITDA MARGIN
14.7%
TTM · consolidated
NET PROFIT MARGIN
8.9%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26